ClinicalTrials.gg
Status unknownNCT04390984Updated Jan 11, 2021

Drug-drug Interaction Study of Gefitinb on Apatinib in NSCLC Patients

A Phase 1 interventional study of Apatinib Mesylate, Gefitinib in NSCLC, sponsored by Jiangsu HengRui Medicine Co., Ltd.. Status unknown at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2021-01-11.

Sponsored by Jiangsu HengRui Medicine Co., Ltd. · Phase 1, Interventional, and Basic science

The sponsor has not verified this record recently (last verified Jan 2021), so the status shown — last known as Recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
22
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Study summary

The primary objective of the study was to assess the effect of gefitinib on the pharmacokinetics of apatinib mesylate in lung cancer patients.

The secondary objective of the study was to assess the pharmacokinetics of gefitinib, and to assess the safety of apatinib mesylate and gefitinib administered in lung cancer patients.

02

Conditions studied

  • NSCLC
03

In context

Lead sponsor

Jiangsu HengRui Medicine Co., Ltd. is the lead sponsor of 573 studies on the registry; 88 are open to participants now.

Of its 10 completed or terminated interventional studies of FDA-regulated products, 1 (10%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. 18-75 years of age.
  2. performance status: level 0\~1;
  3. Anticipated ≥ 12 weeks;
  4. Lung cancer patients;
  5. Major organs in good function;
  6. Agree to take approved method of during the clinical trail and 8 weeks after the last dose of apatinib. Female subject should be negative in the pregnancy test;
  7. Able to comprehend and willing to sign an form (ICF)

Exclusion criteria

Exclusion Criteria:

  1. History of drug allergy, or allergic to apatinib or gefitinib or ingredients;
  2. Squamous cancer, small-cell lung cancer;
  3. Symptomatic central nervous system (CNS)
  4. Hypertension and couldn't be controlled with medicine;
  5. Coagulation disorders;
  6. Clinical significant bleeding in 3 months prior dosing;
  7. Had surgery in four weeks prior dosing;
  8. Disease that affect drug absorption, such as inability to swallow, chronic diarrhea and intestinal obstruction;
  9. Abdominal fistula, gastrointestinal perforation or intraperitoneal abscess in 6 months prior dosing;
  10. Urine protein ≥++, and urine protein ≥1.0g in 24 hours;
  11. Active infection and need antimicrobial treatments;
  12. History of psychiatric substance abuse;
  13. Take any clinical trial drugs within four weeks prior dosing;
  14. Take any drugs that have effect on gastric acid and metabolic enzyme CYP 3A and CYP2D6;
  15. Combined with other viral infections (anti-, anti- positive, positive) or combined with syphilis infection;
  16. Addicted to alcohol and tobacco;
  17. Take grapefruit or grapefruit product, drinks containing caffeine, xanthine and alcohol in 48 hours prior dosing;
  18. The investigator believes that the subjects are not eligible to participate in this trial.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
22 participants (estimated)

Study arms

  • Experimental
    1

    Subjects will be administrated with 500mg apatinib on day 1 and day 12-15, and administrated with gefitinib on day 4-15.

    Drug: Apatinib Mesylate, Gefitinib

Interventions

  • DrugApatinib Mesylate, Gefitinib

    Drug pages: Apatinib · Gefitinib

    Subjects will be administrated with 500mg apatinib on day 1 and day 12-15, and administrated with gefitinib on day 4-15.

06

What researchers measure

Primary outcomes

  1. Cmax

    Maximum Observed Plasma Concentration for apatinib

    Time frame: 0-24 hours

  2. AUC0-τ

    Area Under the Concentration-time Curve From Zero (Pre-dose) to 24 hours

    Time frame: 0-24 hours

07

Study locations

1 of 1 sites recruiting
  • Sun Yat-Sen Univercity Cancer Center
    Guangzhou, Guangdong 510060, China
    Recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started May 2020 (actual). Primary completion is estimated for Feb 2021, 9 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
May 13, 2020
First posted
May 18, 2020
StartActual
May 26, 2020
Primary completionEst.
Feb 2021
CompletionEst.
Mar 2021
Last update
Jan 11, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 11, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04390984
Responsible party
Sponsor
First posted
May 18, 2020
Start date
May 26, 2020
Primary completion
Feb 2021 (estimated)
Completion
Mar 2021 (estimated)
Last update
Jan 11, 2021

Study contacts

Yuya Wang, Ph.D
Contact
wangyuya@hrglobe.cn
13918749176
Li Zhang
principal investigator · Sun Yat-sen University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Jan 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Apatinib · Gefitinib

Start the discussion